Takeda Pharmaceutical Company Limited: Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to

Related Keywords

Japan ,United States ,Japanese ,Daniel Curran ,Abhi Basu ,Jun Saito ,Erin Marie Beals ,European Commission ,Drug Administration ,International Media ,Exchange Commission ,European Union ,Takeda Pharmaceutical Company Limited ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Maribavir Would ,Only Inhibitor ,Without Resistance ,Opinion Based ,Conventional Therapies ,Study Week ,Most Common ,Serious Post Transplant Infections ,Can Lead ,Transplanted Organ ,Medicinal Products ,Human Use ,Rare Diseases Therapeutic Area ,Rare Genetics ,Plasma Derived Therapies ,Looking Statements ,Annual Report ,Reviews Drug ,Stem Cell ,Takeda ,Harmaceutical ,Company ,Imited ,Eceives ,Positive ,Thmp ,Opinion ,Maribavir ,Treatment ,Adults ,Most ,Transplant ,Cytomegalovirus ,Refractory ,Ith ,Without ,Resistance ,Rior ,Therapies ,